Serum Level of Interleukin-38 in Vitiligo Patients and its Alterations After Narrowband Ultraviolet Light - B Phototherapy | ||||
| Benha Journal of Applied Sciences | ||||
| Article 10, Volume 9, Issue 11, November 2024, Page 67-72 PDF (415.01 K) | ||||
| Document Type: Original Research Papers | ||||
| DOI: 10.21608/bjas.2024.339176.1540 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Sherine Hosny Ahmed1; Nader Nasr Nazmy2; Amany Kasem Shahat3; Heba Abd El-Daim Ali  4
| ||||
| 1Professor of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University | ||||
| 2Lecturer of Dermatology, Venereology and Andrology, Faculty of Medicine, Benha University | ||||
| 3Lecturer of Medical Microbiology and Immunology, Faculty of Medicine, Benha University | ||||
| 4(M.B.B.Ch., Faculty of Medicine, Benha University) | ||||
| Abstract | ||||
| Background: Vitiligo is an autoimmune condition characterized by melanocyte loss and depigmented patches. Cytokines, especially those in the Th1 and Th17 pathways, play pivotal roles in its pathogenesis. Interleukin (IL)-38, a cytokine involved in immune regulation, may influence vitiligo progression and treatment outcomes, particularly in response to narrowband ultraviolet B (NB-UVB) therapy. Aim: This study aimed to assess serum IL-38 levels in vitiligo patients compared to healthy controls and evaluate correlations between IL-38 levels, disease severity indices, and treatment response to NB-UVB. Methods: A case-control study was conducted on 45 participants from the Dermatology Clinic at Benha University Hospitals. Group I included 15 patients with active vitiligo, Group II included 15 patients with stable vitiligo, and Group III included 15 healthy controls. Disease severity was assessed using Vitiligo Area Scoring Index (VASI) and Vitiligo Disease Activity (VIDA) scores, while quality of life was evaluated with the Dermatological Life Quality Index (DLQI). Serum IL-38 levels were measured pre- and post-NB-UVB therapy. Results: IL-38 levels were significantly elevated in vitiligo patients compared to controls (P < 0.001), with generalized vitiligo showing the highest levels. Post-treatment, IL-38 levels decreased significantly (P = 0.003), correlating with improvements in VASI scores (P < 0.001). IL-38 demonstrated strong sensitivity and specificity for predicting vitiligo (AUC = 0.891). Conclusion: Serum IL-38 is a potential biomarker for disease activity and treatment efficacy in vitiligo. Its role in modulating inflammation suggests therapeutic and diagnostic implications. | ||||
| Keywords | ||||
| Vitiligo; Interleukin-38 (IL-38); Narrowband Ultraviolet B (NB-UVB) Phototherapy | ||||
|
Statistics Article View: 307 PDF Download: 175 |
||||
